Gradient Investments LLC Cuts Stock Position in Danaher Co. (NYSE:DHR)

Gradient Investments LLC trimmed its stake in shares of Danaher Co. (NYSE:DHR) by 5.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 882 shares of the conglomerate’s stock after selling 52 shares during the quarter. Gradient Investments LLC’s holdings in Danaher were worth $202,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. FMR LLC raised its holdings in shares of Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after acquiring an additional 3,217,631 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after purchasing an additional 535,254 shares in the last quarter. International Assets Investment Management LLC raised its stake in Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after purchasing an additional 428,897 shares during the last quarter. Montrusco Bolton Investments Inc. lifted its holdings in Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after purchasing an additional 397,671 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec boosted its stake in Danaher by 82.4% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 653,375 shares of the conglomerate’s stock worth $181,651,000 after purchasing an additional 295,187 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Up 0.1 %

DHR opened at $245.95 on Monday. The firm has a market cap of $177.65 billion, a P/E ratio of 46.94, a PEG ratio of 4.43 and a beta of 0.83. The business’s fifty day simple moving average is $235.33 and its 200 day simple moving average is $253.54. Danaher Co. has a 52 week low of $225.42 and a 52 week high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of recent research reports. UBS Group cut their price objective on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research report on Thursday, October 31st. Robert W. Baird dropped their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Finally, Guggenheim initiated coverage on shares of Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average target price of $285.55.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.